Outcome in patients with myasthenia gravis Managed with or without Thymectomy by Bano, Safia et al.
Pakistan Journal of Neurological 
Sciences (PJNS) 
Volume 14 Issue 4 Article 8 
12-2019 
Outcome in patients with myasthenia gravis Managed with or 
without Thymectomy 
Safia Bano 
KEMU, Lahore Pakistan, safiabano207@gmail.com 
Muhammad Athar Javed 
KEMU, Lahore Pakistan 
Waqas Arshad 
KEMU, Lahore Pakistan 
Follow this and additional works at: https://ecommons.aku.edu/pjns 
 Part of the Neurology Commons 
Recommended Citation 
Bano, Safia; Javed, Muhammad Athar; and Arshad, Waqas (2019) "Outcome in patients with myasthenia 
gravis Managed with or without Thymectomy," Pakistan Journal of Neurological Sciences (PJNS): Vol. 14 : 
Iss. 4 , Article 8. 
Available at: https://ecommons.aku.edu/pjns/vol14/iss4/8 
OUTCOME IN PATIENTS WITH MYASTHENIA GRAVIS 
MANAGED WITH OR WITHOUT THYMECTOMY
Safia Bano1, Muhammad Athar Javed2, Waqas Arshad3
1Assistant Professor, Neurology department, MHL/KEMU, Lahore, 2Professor, Neurology department, MHL/KEMU, Lahore,
Correspondence to: Safia Bano, E-mail: safiabano207@gmail.com
 
Date of submission: April 17, 2019 Date of revision: September 10, 2019 Date of acceptance: September 25, 2019
1 3P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S
ABSTRACT
BACKGROUND: Myasthenia gravis is a chronic acquired autoimmune disorder in which autoantibodies are produced 
against acetylcholine receptors present on neuromuscular junction. It results in neuromuscular transmission blockage 
hence muscle weakness occurs. Thymus gland is considered as having crucial role in development of these antibodies. 
Screening patients for thymoma and removal of the thymus gland with surgery has an important aspect in 
management of disease.
  
OBJECTIVE: To compare the clinical outcome of patients with myasthenia gravis treated with or without thymectomy.
MATERIAL AND METHODS: Study design: Retrospective observational comparative study. 
SETTING: Department of Neurology, Mayo hospital, Lahore. Duration: patients with myasthenia gravis from 2014 to 
2017.
Procedure: 40 Patients with myasthenia gravis Osserman stage from 1 to 4 treated from 2014 to 2017, irrespective 
of age and gender were included. Diagnosis of myasthenia Gravis was based on positive EMG study, acetylcholine 
receptor antibodies and Pyridostigmine test (as Edrophonium was not available). Records of 20 patients that 
underwent thymectomy and 20 patients which were managed conservatively were obtained. Outcome in patients 
having thymectomy was assessed on the basis of MGFA Post intervention status after 1year.
RESULTS: study sample (40 patients) includes 15 males and 25 females. The mean age of patients was 33 years 
(range 14 to 63, SD 11.2). In thymectomy group, 7 males and 13 females (age range 16 to 53years, means age 32, 
SD 10) that underwent thymectomy. With thymectomy, 14 patients improved, 6 remained unchanged while no 
patients showed worsening or exacerbation of their symptoms. There were 8 males and 12 females of age 14 to 63 
years that were managed without thymectomy. Of them, 2 patients improved, 6 remained unchanged, and 12 had 
worsened symptoms while no patients showed exacerbated symptoms. The difference among the two groups was 
statistically significant (p<0.05).
Conclusion: After thymectomy there was a substantial dose reduction in antimyasthenic treatment with minimum or 
no exacerbation as compared to patients without thymectomy. So all patients of myasthenia gravis should be offered 
thymectomy as a part of treatment. This conclusion is in line with guidelines for the management of myasthenia gravis.
KEY WORDS: myasthenia Gravis, thymectomy, complete remission.
INTRODUCTION
Myasthenia gravis (MG) is a chronic acquired 
autoimmune disease of neuromuscular junction 
leading to muscular weakness. There are large number 
of molecules, including ion channels and various 
proteins, present at the neuromuscular junction, which 
can be targeted by autoantibodies resulting in blockage 
of neuromuscular transmission.1
Population-based studies of the epidemiology of 
myasthenia gravis have been conducted for over 50 
years. A clear increasing trend has been reported. 
Recently, estimated prevalence is about 20 per 
100,000 in United States.2 Patients with myasthenia 
gravis have fluctuating fatigability in voluntary muscles 
of body predominantly ocular, oropharyngeal, facial, 
respiratory and limbs muscles.3 The role of thymus 
gland in pathogenesis of myasthenia gravis is 
incompletely understood, but consider as major driving 
factor for the production of acetylcholine receptor 
autoantibodies. Mostly patients with myasthenia gravis 
have thymic abnormalities, i.e >50% is thymic 
hyperplasia, and 10–15% is a thymic neoplasm.4 
Treatment is with pharmacological measures with or 
without thymic surgery. Medication consists mainly of 
acetylcholinesterase inhibitors (such as neostigmine, 
pyridostigmine) which reduce the breakdown of 
acetylcholine at the neuromuscular junction and hence 
increase the amount of acetyl choline available to act 
on the remaining post synaptic receptors. Alongside 
with this symptomatic therapy, immunomodulators are 
used to dumpen the autoimmune response.5 
Thymectomy is one of the treatment modality  to treat 
MG.6 The removal of thymus gland with surgery has 
been an alternative  treatment modality  for myasthenia 
gravis since Blalock had performed a successful 
thymectomy in young female with MG and thymus 
cysts.7  We aimed to conduct this study to find the 
beneficial role of thymectomy for myasthenia Gravis 
patients in recovery from myasthenia.
We aimed to conduct this study to understand the 
potential benefits of thymectomy in our myasthenia 
gravis patients. We hypothesized that patients treated 
with thymectomy will have better clinical outcome, 
compared to the patients managed purely with 
pharmacological means.
OBJECTIVE
To compare the clinical outcome of Myasthenia Gravis 
patients treated with or without thymectomy.
MATERIAL AND METHODS
Study design: Retrospective, observational 
comparative study.
Setting: Department of Neurology, Mayo hospital, 
Lahore.
Duration: Patients with MG treated from 2014 to 
2017.
Sampling technique: Non-probability, consecutive 
sampling.
Selection criteria:
Inclusion criteria: all patients with myasthenia gravis, 
Osserman stage from 1 to 4 treated from 2014 to 
2017, irrespective of age and gender.
Exclusion criteria: Patients with recurrent myasthenia 
Gravis, ocular myasthenia with normal thymus having 
disease less than one year, HIV patients.
Data collection: After taking approval from ethical 
committee, medical record of 40 patients was 
obtained. Diagnosis of myasthenia gravis was based on 
positive EMG/RNS study, acetylcholine receptor 
antibodies and Pyridostigmine test (as Edrophonium 
was not available). Record of 20 patients that 
underwent thymectomy and 20 patients that did not 
get thymectomy was obtained. Then patients were 
called for follow-up in OPD and clinical assessment was 
be done for myasthenia Gravis. Outcome in patients 
having Thymectomy assessed on the basis of MGFA 
Post intervention. Complete remission of disease was 
defined as patients with normal muscle strength, 
without medications for myasthenia gravis for at least 
1years (fig 1). Data was entered and analysed by SPSS 
21. Both groups were compared for complete 
remission by using chi-square test and p-value≤0.05 
was considered as statistically significant
RESULTS
Study sample (total 40 patients) includes 15 males 
and 25 females. The mean age was 33 years (range 14 
to 63, SD 11.2). Table 1 In thymectomy group, 7 males 
and 13 females (age range 16 to 53 years, Mean age 
was 32, SD 10) that underwent thymectomy. With 
thymectomy, 14 patients improved, 6 remained 
unchanged while no patients showed worsened or 
exacerbated symptoms. There were 8 males and 12 
females of age 14 to 63 years that did not undergo 
thymectomy. Without thymectomy, 2 patients 
improved, 6 remained unchanged. The difference was 
significant (p<0.05). Fig 2 In both groups, complete 
stable remission was absent in all patients, 
pharmacologic remission was also nil while minimal 
manifestation status 3 was observed in all patients in 
both group (100%). Fig 3
DISCUSSION
Thymic abnormalities like Thymomas are present in 
10% of patients with myasthenia gravis, and 
thymectomy is mandatory.8 Mostly published literature 
on thymectomy has consisted of either non-randomized 
observational trials or case-control studies, mainly 
relying on remission rates.9 10 The potential benefits of 
thymectomy in improving clinical outcomes in 
myasthenia gravis (MG)  patients without thymic 
abnormalities  is still under study, despite the fact that 
it is used in clinical practice for more than  60 years.11 
thymectomy improves various clinical parameters and 
reduces the need for pharmacological treatment in 
patients with myasthenia gravis. When combined with 
standard immunosuppressive therapy, surgery gives 
more benefits as compared with steroids alone. 
Importantly it also decreases the requirement for 
steroids or immune suppressants, hence their side 
effects.12 In our study, we observed that patients in 
thymectomy group were improved clinically, 
pharmacological remission with minimal manifestation 
(MM3). Patients in non-thymectomy group had 
frequent exacerbations than thymectomy 
group.Regardless of MG condition, all patient should 
undergo thymectomy (with or without thymoma). 
Thymectomy is indicated in myasthenia gravis to 
improve clinical outcomes and reduce the need for 
immunosuppressive drugs in patients with myasthenia 
gravis.13 According to another trial, 26.0% patients 
were in complete stable remission, 35.6% patients 
were without symptoms on reduced medications, and 
17.8% patients had clinical improvement even further 
dose reduction. Overall, 79.4% of patients benefited 
with surgery, 8.2% had unchanged clinical status in 
disease, and 12.3% showed worsening clinically.14 
However, the complete stable remission rate (26.0%) 
was less as compared to other reported series 
(14%-47%).15-17 In another trial, 113 consecutive 
thymectomies were done in patients with MG, 
complications rate was 14%. Complete stable 
remission was noticed in 21% of patients, and 
significant improvement of MG in 54%, so total 
beneficial rate was 75% and 14% had unchanged 
status, and 11% (10 of 92) were worsened clinically.18 
In another trial, 42 patients with myasthenia gravis 
having thymoma were compared with 42 MG patients 
without thymoma using a modified Osserman 
classification. The mean Osserman grades at time of 
diagnosis, 6 months, 5 and 10 years post-thymectomy 
did not differ among groups. Results indicate that 
thymoma should not be considered as major poor 
prognostic factor for the long-term outcome of MG.19 
Thymectomy exhibits satisfactory long-term clinical 
benefits in patients with myasthenia gravis without 
thymic abnormalities. Although presence of anti-MuSK 
antibodies correlates with poor response to operation.20 
Thymectomy improved clinical status over a 3-year 
period in patients with myasthenia gravis without 
thymic abnormalities.
 
CONCLUSION
After thymectomy there is substantial dose reduction in 
anti myasthenic treatment with minimum or no 
exacerbation as compared to non-thymectomy 
patients. There are significant better results with 
thymectomy. So all patients of myasthenia gravis 
should be offered thymectomy as a part of treatment.
Fig 1: criteria for assessment of Myasthenia Gravis 
patients after thymectomy (MGFA-PIS)
Complete remission: pt. no S/S of MG for one year 
and no medication 
Remission CSR: no clinical weakness on examination 
Pharmacological remission: same as CSR, taking 
medicine but no on cholinesterase inhibitors 
MM: No symptoms but weakness on clinical 
examination 
MM0: pt. did not receive MG treatment for one year  
MM1: pt. is taking immunosuppression but no 
cholinesterase inhibitors
MM2: pt. is taking cholinesterase inhibitors <120mg 
pyridostigmine for a year
MM3: pt. is receiving both immunosuppressant and 
cholinesterase inhibitor
CHANGE IN STATUS
IMPROVED: a decrease in clinical manifestations or 
dose reduction in previous treatment Unchanged: no 
change in clinical manifestations or dose reduction in 
previous treatment 
WORSE: increase in pre-treatment clinical 
manifestations or dose
EXACERBATION: pt who is fulfilling criteria of CSR or 
PR but showing clinical worsening 
DIED: death of MG pt. either on treatment or after 
thymectomy
Fig 2: Comparison of outcome in both groups (p>0.05)
Fig 2: Comparison of long term outcome in both 
groups
Fig 3: Comparison of long-term outcome in 
both groups
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INTRODUCTION
Myasthenia gravis (MG) is a chronic acquired 
autoimmune disease of neuromuscular junction 
leading to muscular weakness. There are large number 
of molecules, including ion channels and various 
proteins, present at the neuromuscular junction, which 
can be targeted by autoantibodies resulting in blockage 
of neuromuscular transmission.1
Population-based studies of the epidemiology of 
myasthenia gravis have been conducted for over 50 
years. A clear increasing trend has been reported. 
Recently, estimated prevalence is about 20 per 
100,000 in United States.2 Patients with myasthenia 
gravis have fluctuating fatigability in voluntary muscles 
of body predominantly ocular, oropharyngeal, facial, 
respiratory and limbs muscles.3 The role of thymus 
gland in pathogenesis of myasthenia gravis is 
incompletely understood, but consider as major driving 
factor for the production of acetylcholine receptor 
autoantibodies. Mostly patients with myasthenia gravis 
have thymic abnormalities, i.e >50% is thymic 
hyperplasia, and 10–15% is a thymic neoplasm.4 
Treatment is with pharmacological measures with or 
without thymic surgery. Medication consists mainly of 
acetylcholinesterase inhibitors (such as neostigmine, 
pyridostigmine) which reduce the breakdown of 
acetylcholine at the neuromuscular junction and hence 
increase the amount of acetyl choline available to act 
on the remaining post synaptic receptors. Alongside 
with this symptomatic therapy, immunomodulators are 
used to dumpen the autoimmune response.5 
Thymectomy is one of the treatment modality  to treat 
MG.6 The removal of thymus gland with surgery has 
been an alternative  treatment modality  for myasthenia 
gravis since Blalock had performed a successful 
thymectomy in young female with MG and thymus 
cysts.7  We aimed to conduct this study to find the 
beneficial role of thymectomy for myasthenia Gravis 
patients in recovery from myasthenia.
We aimed to conduct this study to understand the 
potential benefits of thymectomy in our myasthenia 
gravis patients. We hypothesized that patients treated 
with thymectomy will have better clinical outcome, 
compared to the patients managed purely with 
pharmacological means.
OBJECTIVE
To compare the clinical outcome of Myasthenia Gravis 
patients treated with or without thymectomy.
MATERIAL AND METHODS
Study design: Retrospective, observational 
comparative study.
Setting: Department of Neurology, Mayo hospital, 
Lahore.
Duration: Patients with MG treated from 2014 to 
2017.
Sampling technique: Non-probability, consecutive 
sampling.
Selection criteria:
Inclusion criteria: all patients with myasthenia gravis, 
Osserman stage from 1 to 4 treated from 2014 to 
2017, irrespective of age and gender.
Exclusion criteria: Patients with recurrent myasthenia 
Gravis, ocular myasthenia with normal thymus having 
disease less than one year, HIV patients.
Data collection: After taking approval from ethical 
committee, medical record of 40 patients was 
obtained. Diagnosis of myasthenia gravis was based on 
positive EMG/RNS study, acetylcholine receptor 
antibodies and Pyridostigmine test (as Edrophonium 
was not available). Record of 20 patients that 
underwent thymectomy and 20 patients that did not 
get thymectomy was obtained. Then patients were 
called for follow-up in OPD and clinical assessment was 
be done for myasthenia Gravis. Outcome in patients 
having Thymectomy assessed on the basis of MGFA 
Post intervention. Complete remission of disease was 
defined as patients with normal muscle strength, 
without medications for myasthenia gravis for at least 
1years (fig 1). Data was entered and analysed by SPSS 
21. Both groups were compared for complete 
remission by using chi-square test and p-value≤0.05 
was considered as statistically significant
RESULTS
Study sample (total 40 patients) includes 15 males 
and 25 females. The mean age was 33 years (range 14 
to 63, SD 11.2). Table 1 In thymectomy group, 7 males 
and 13 females (age range 16 to 53 years, Mean age 
was 32, SD 10) that underwent thymectomy. With 
thymectomy, 14 patients improved, 6 remained 
unchanged while no patients showed worsened or 
exacerbated symptoms. There were 8 males and 12 
females of age 14 to 63 years that did not undergo 
thymectomy. Without thymectomy, 2 patients 
improved, 6 remained unchanged. The difference was 
significant (p<0.05). Fig 2 In both groups, complete 
stable remission was absent in all patients, 
pharmacologic remission was also nil while minimal 
manifestation status 3 was observed in all patients in 
both group (100%). Fig 3
DISCUSSION
Thymic abnormalities like Thymomas are present in 
10% of patients with myasthenia gravis, and 
thymectomy is mandatory.8 Mostly published literature 
on thymectomy has consisted of either non-randomized 
observational trials or case-control studies, mainly 
relying on remission rates.9 10 The potential benefits of 
thymectomy in improving clinical outcomes in 
myasthenia gravis (MG)  patients without thymic 
abnormalities  is still under study, despite the fact that 
it is used in clinical practice for more than  60 years.11 
thymectomy improves various clinical parameters and 
reduces the need for pharmacological treatment in 
patients with myasthenia gravis. When combined with 
standard immunosuppressive therapy, surgery gives 
more benefits as compared with steroids alone. 
Importantly it also decreases the requirement for 
steroids or immune suppressants, hence their side 
effects.12 In our study, we observed that patients in 
thymectomy group were improved clinically, 
pharmacological remission with minimal manifestation 
(MM3). Patients in non-thymectomy group had 
frequent exacerbations than thymectomy 
group.Regardless of MG condition, all patient should 
undergo thymectomy (with or without thymoma). 
Thymectomy is indicated in myasthenia gravis to 
improve clinical outcomes and reduce the need for 
immunosuppressive drugs in patients with myasthenia 
gravis.13 According to another trial, 26.0% patients 
were in complete stable remission, 35.6% patients 
were without symptoms on reduced medications, and 
17.8% patients had clinical improvement even further 
dose reduction. Overall, 79.4% of patients benefited 
with surgery, 8.2% had unchanged clinical status in 
disease, and 12.3% showed worsening clinically.14 
However, the complete stable remission rate (26.0%) 
was less as compared to other reported series 
(14%-47%).15-17 In another trial, 113 consecutive 
thymectomies were done in patients with MG, 
complications rate was 14%. Complete stable 
remission was noticed in 21% of patients, and 
significant improvement of MG in 54%, so total 
beneficial rate was 75% and 14% had unchanged 
status, and 11% (10 of 92) were worsened clinically.18 
In another trial, 42 patients with myasthenia gravis 
having thymoma were compared with 42 MG patients 
without thymoma using a modified Osserman 
classification. The mean Osserman grades at time of 
diagnosis, 6 months, 5 and 10 years post-thymectomy 
did not differ among groups. Results indicate that 
thymoma should not be considered as major poor 
prognostic factor for the long-term outcome of MG.19 
Thymectomy exhibits satisfactory long-term clinical 
benefits in patients with myasthenia gravis without 
thymic abnormalities. Although presence of anti-MuSK 
antibodies correlates with poor response to operation.20 
Thymectomy improved clinical status over a 3-year 
period in patients with myasthenia gravis without 
thymic abnormalities.
 
CONCLUSION
After thymectomy there is substantial dose reduction in 
anti myasthenic treatment with minimum or no 
exacerbation as compared to non-thymectomy 
patients. There are significant better results with 
thymectomy. So all patients of myasthenia gravis 
should be offered thymectomy as a part of treatment.
Fig 1: criteria for assessment of Myasthenia Gravis 
patients after thymectomy (MGFA-PIS)
Complete remission: pt. no S/S of MG for one year 
and no medication 
Remission CSR: no clinical weakness on examination 
Pharmacological remission: same as CSR, taking 
medicine but no on cholinesterase inhibitors 
MM: No symptoms but weakness on clinical 
examination 
MM0: pt. did not receive MG treatment for one year  
MM1: pt. is taking immunosuppression but no 
cholinesterase inhibitors
MM2: pt. is taking cholinesterase inhibitors <120mg 
pyridostigmine for a year
MM3: pt. is receiving both immunosuppressant and 
cholinesterase inhibitor
CHANGE IN STATUS
IMPROVED: a decrease in clinical manifestations or 
dose reduction in previous treatment Unchanged: no 
change in clinical manifestations or dose reduction in 
previous treatment 
WORSE: increase in pre-treatment clinical 
manifestations or dose
EXACERBATION: pt who is fulfilling criteria of CSR or 
PR but showing clinical worsening 
DIED: death of MG pt. either on treatment or after 
thymectomy
Fig 2: Comparison of outcome in both groups (p>0.05)
Fig 2: Comparison of long term outcome in both 
groups
Fig 3: Comparison of long-term outcome in 
both groups
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INTRODUCTION
Myasthenia gravis (MG) is a chronic acquired 
autoimmune disease of neuromuscular junction 
leading to muscular weakness. There are large number 
of molecules, including ion channels and various 
proteins, present at the neuromuscular junction, which 
can be targeted by autoantibodies resulting in blockage 
of neuromuscular transmission.1
Population-based studies of the epidemiology of 
myasthenia gravis have been conducted for over 50 
years. A clear increasing trend has been reported. 
Recently, estimated prevalence is about 20 per 
100,000 in United States.2 Patients with myasthenia 
gravis have fluctuating fatigability in voluntary muscles 
of body predominantly ocular, oropharyngeal, facial, 
respiratory and limbs muscles.3 The role of thymus 
gland in pathogenesis of myasthenia gravis is 
incompletely understood, but consider as major driving 
factor for the production of acetylcholine receptor 
autoantibodies. Mostly patients with myasthenia gravis 
have thymic abnormalities, i.e >50% is thymic 
hyperplasia, and 10–15% is a thymic neoplasm.4 
Treatment is with pharmacological measures with or 
without thymic surgery. Medication consists mainly of 
acetylcholinesterase inhibitors (such as neostigmine, 
pyridostigmine) which reduce the breakdown of 
acetylcholine at the neuromuscular junction and hence 
increase the amount of acetyl choline available to act 
on the remaining post synaptic receptors. Alongside 
with this symptomatic therapy, immunomodulators are 
used to dumpen the autoimmune response.5 
Thymectomy is one of the treatment modality  to treat 
MG.6 The removal of thymus gland with surgery has 
been an alternative  treatment modality  for myasthenia 
gravis since Blalock had performed a successful 
thymectomy in young female with MG and thymus 
cysts.7  We aimed to conduct this study to find the 
beneficial role of thymectomy for myasthenia Gravis 
patients in recovery from myasthenia.
We aimed to conduct this study to understand the 
potential benefits of thymectomy in our myasthenia 
gravis patients. We hypothesized that patients treated 
with thymectomy will have better clinical outcome, 
compared to the patients managed purely with 
pharmacological means.
OBJECTIVE
To compare the clinical outcome of Myasthenia Gravis 
patients treated with or without thymectomy.
MATERIAL AND METHODS
Study design: Retrospective, observational 
comparative study.
Setting: Department of Neurology, Mayo hospital, 
Lahore.
Duration: Patients with MG treated from 2014 to 
2017.
Sampling technique: Non-probability, consecutive 
sampling.
Selection criteria:
Inclusion criteria: all patients with myasthenia gravis, 
Osserman stage from 1 to 4 treated from 2014 to 
2017, irrespective of age and gender.
Exclusion criteria: Patients with recurrent myasthenia 
Gravis, ocular myasthenia with normal thymus having 
disease less than one year, HIV patients.
Data collection: After taking approval from ethical 
committee, medical record of 40 patients was 
obtained. Diagnosis of myasthenia gravis was based on 
positive EMG/RNS study, acetylcholine receptor 
antibodies and Pyridostigmine test (as Edrophonium 
was not available). Record of 20 patients that 
underwent thymectomy and 20 patients that did not 
get thymectomy was obtained. Then patients were 
called for follow-up in OPD and clinical assessment was 
be done for myasthenia Gravis. Outcome in patients 
having Thymectomy assessed on the basis of MGFA 
Post intervention. Complete remission of disease was 
defined as patients with normal muscle strength, 
without medications for myasthenia gravis for at least 
1years (fig 1). Data was entered and analysed by SPSS 
21. Both groups were compared for complete 
remission by using chi-square test and p-value≤0.05 
was considered as statistically significant
RESULTS
Study sample (total 40 patients) includes 15 males 
and 25 females. The mean age was 33 years (range 14 
to 63, SD 11.2). Table 1 In thymectomy group, 7 males 
and 13 females (age range 16 to 53 years, Mean age 
was 32, SD 10) that underwent thymectomy. With 
thymectomy, 14 patients improved, 6 remained 
unchanged while no patients showed worsened or 
exacerbated symptoms. There were 8 males and 12 
females of age 14 to 63 years that did not undergo 
thymectomy. Without thymectomy, 2 patients 
improved, 6 remained unchanged. The difference was 
significant (p<0.05). Fig 2 In both groups, complete 
stable remission was absent in all patients, 
pharmacologic remission was also nil while minimal 
manifestation status 3 was observed in all patients in 
both group (100%). Fig 3
DISCUSSION
Thymic abnormalities like Thymomas are present in 
10% of patients with myasthenia gravis, and 
thymectomy is mandatory.8 Mostly published literature 
on thymectomy has consisted of either non-randomized 
observational trials or case-control studies, mainly 
relying on remission rates.9 10 The potential benefits of 
thymectomy in improving clinical outcomes in 
myasthenia gravis (MG)  patients without thymic 
abnormalities  is still under study, despite the fact that 
it is used in clinical practice for more than  60 years.11 
thymectomy improves various clinical parameters and 
reduces the need for pharmacological treatment in 
patients with myasthenia gravis. When combined with 
standard immunosuppressive therapy, surgery gives 
more benefits as compared with steroids alone. 
Importantly it also decreases the requirement for 
steroids or immune suppressants, hence their side 
effects.12 In our study, we observed that patients in 
thymectomy group were improved clinically, 
pharmacological remission with minimal manifestation 
(MM3). Patients in non-thymectomy group had 
frequent exacerbations than thymectomy 
group.Regardless of MG condition, all patient should 
undergo thymectomy (with or without thymoma). 
Thymectomy is indicated in myasthenia gravis to 
improve clinical outcomes and reduce the need for 
immunosuppressive drugs in patients with myasthenia 
gravis.13 According to another trial, 26.0% patients 
were in complete stable remission, 35.6% patients 
were without symptoms on reduced medications, and 
17.8% patients had clinical improvement even further 
dose reduction. Overall, 79.4% of patients benefited 
with surgery, 8.2% had unchanged clinical status in 
disease, and 12.3% showed worsening clinically.14 
However, the complete stable remission rate (26.0%) 
was less as compared to other reported series 
(14%-47%).15-17 In another trial, 113 consecutive 
thymectomies were done in patients with MG, 
complications rate was 14%. Complete stable 
remission was noticed in 21% of patients, and 
significant improvement of MG in 54%, so total 
beneficial rate was 75% and 14% had unchanged 
status, and 11% (10 of 92) were worsened clinically.18 
In another trial, 42 patients with myasthenia gravis 
having thymoma were compared with 42 MG patients 
without thymoma using a modified Osserman 
classification. The mean Osserman grades at time of 
diagnosis, 6 months, 5 and 10 years post-thymectomy 
did not differ among groups. Results indicate that 
thymoma should not be considered as major poor 
prognostic factor for the long-term outcome of MG.19 
Thymectomy exhibits satisfactory long-term clinical 
benefits in patients with myasthenia gravis without 
thymic abnormalities. Although presence of anti-MuSK 
antibodies correlates with poor response to operation.20 
Thymectomy improved clinical status over a 3-year 
period in patients with myasthenia gravis without 
thymic abnormalities.
 
CONCLUSION
After thymectomy there is substantial dose reduction in 
anti myasthenic treatment with minimum or no 
exacerbation as compared to non-thymectomy 
patients. There are significant better results with 
thymectomy. So all patients of myasthenia gravis 
should be offered thymectomy as a part of treatment.
Fig 1: criteria for assessment of Myasthenia Gravis 
patients after thymectomy (MGFA-PIS)
Complete remission: pt. no S/S of MG for one year 
and no medication 
Remission CSR: no clinical weakness on examination 
Pharmacological remission: same as CSR, taking 
medicine but no on cholinesterase inhibitors 
MM: No symptoms but weakness on clinical 
examination 
MM0: pt. did not receive MG treatment for one year  
MM1: pt. is taking immunosuppression but no 
cholinesterase inhibitors
MM2: pt. is taking cholinesterase inhibitors <120mg 
pyridostigmine for a year
MM3: pt. is receiving both immunosuppressant and 
cholinesterase inhibitor
CHANGE IN STATUS
IMPROVED: a decrease in clinical manifestations or 
dose reduction in previous treatment Unchanged: no 
change in clinical manifestations or dose reduction in 
previous treatment 
WORSE: increase in pre-treatment clinical 
manifestations or dose
EXACERBATION: pt who is fulfilling criteria of CSR or 
PR but showing clinical worsening 
DIED: death of MG pt. either on treatment or after 
thymectomy
Fig 2: Comparison of outcome in both groups (p>0.05)
Fig 2: Comparison of long term outcome in both 
groups
Fig 3: Comparison of long-term outcome in 
both groups
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INTRODUCTION
Myasthenia gravis (MG) is a chronic acquired 
autoimmune disease of neuromuscular junction 
leading to muscular weakness. There are large number 
of molecules, including ion channels and various 
proteins, present at the neuromuscular junction, which 
can be targeted by autoantibodies resulting in blockage 
of neuromuscular transmission.1
Population-based studies of the epidemiology of 
myasthenia gravis have been conducted for over 50 
years. A clear increasing trend has been reported. 
Recently, estimated prevalence is about 20 per 
100,000 in United States.2 Patients with myasthenia 
gravis have fluctuating fatigability in voluntary muscles 
of body predominantly ocular, oropharyngeal, facial, 
respiratory and limbs muscles.3 The role of thymus 
gland in pathogenesis of myasthenia gravis is 
incompletely understood, but consider as major driving 
factor for the production of acetylcholine receptor 
autoantibodies. Mostly patients with myasthenia gravis 
have thymic abnormalities, i.e >50% is thymic 
hyperplasia, and 10–15% is a thymic neoplasm.4 
Treatment is with pharmacological measures with or 
without thymic surgery. Medication consists mainly of 
acetylcholinesterase inhibitors (such as neostigmine, 
pyridostigmine) which reduce the breakdown of 
acetylcholine at the neuromuscular junction and hence 
increase the amount of acetyl choline available to act 
on the remaining post synaptic receptors. Alongside 
with this symptomatic therapy, immunomodulators are 
used to dumpen the autoimmune response.5 
Thymectomy is one of the treatment modality  to treat 
MG.6 The removal of thymus gland with surgery has 
been an alternative  treatment modality  for myasthenia 
gravis since Blalock had performed a successful 
thymectomy in young female with MG and thymus 
cysts.7  We aimed to conduct this study to find the 
beneficial role of thymectomy for myasthenia Gravis 
patients in recovery from myasthenia.
We aimed to conduct this study to understand the 
potential benefits of thymectomy in our myasthenia 
gravis patients. We hypothesized that patients treated 
with thymectomy will have better clinical outcome, 
compared to the patients managed purely with 
pharmacological means.
OBJECTIVE
To compare the clinical outcome of Myasthenia Gravis 
patients treated with or without thymectomy.
MATERIAL AND METHODS
Study design: Retrospective, observational 
comparative study.
Setting: Department of Neurology, Mayo hospital, 
Lahore.
Duration: Patients with MG treated from 2014 to 
2017.
Sampling technique: Non-probability, consecutive 
sampling.
Selection criteria:
Inclusion criteria: all patients with myasthenia gravis, 
Osserman stage from 1 to 4 treated from 2014 to 
2017, irrespective of age and gender.
Exclusion criteria: Patients with recurrent myasthenia 
Gravis, ocular myasthenia with normal thymus having 
disease less than one year, HIV patients.
Data collection: After taking approval from ethical 
committee, medical record of 40 patients was 
obtained. Diagnosis of myasthenia gravis was based on 
positive EMG/RNS study, acetylcholine receptor 
antibodies and Pyridostigmine test (as Edrophonium 
was not available). Record of 20 patients that 
underwent thymectomy and 20 patients that did not 
get thymectomy was obtained. Then patients were 
called for follow-up in OPD and clinical assessment was 
be done for myasthenia Gravis. Outcome in patients 
having Thymectomy assessed on the basis of MGFA 
Post intervention. Complete remission of disease was 
defined as patients with normal muscle strength, 
without medications for myasthenia gravis for at least 
1years (fig 1). Data was entered and analysed by SPSS 
21. Both groups were compared for complete 
remission by using chi-square test and p-value≤0.05 
was considered as statistically significant
RESULTS
Study sample (total 40 patients) includes 15 males 
and 25 females. The mean age was 33 years (range 14 
to 63, SD 11.2). Table 1 In thymectomy group, 7 males 
and 13 females (age range 16 to 53 years, Mean age 
was 32, SD 10) that underwent thymectomy. With 
thymectomy, 14 patients improved, 6 remained 
unchanged while no patients showed worsened or 
exacerbated symptoms. There were 8 males and 12 
females of age 14 to 63 years that did not undergo 
thymectomy. Without thymectomy, 2 patients 
improved, 6 remained unchanged. The difference was 
significant (p<0.05). Fig 2 In both groups, complete 
stable remission was absent in all patients, 
pharmacologic remission was also nil while minimal 
manifestation status 3 was observed in all patients in 
both group (100%). Fig 3
DISCUSSION
Thymic abnormalities like Thymomas are present in 
10% of patients with myasthenia gravis, and 
thymectomy is mandatory.8 Mostly published literature 
on thymectomy has consisted of either non-randomized 
observational trials or case-control studies, mainly 
relying on remission rates.9 10 The potential benefits of 
thymectomy in improving clinical outcomes in 
myasthenia gravis (MG)  patients without thymic 
abnormalities  is still under study, despite the fact that 
it is used in clinical practice for more than  60 years.11 
thymectomy improves various clinical parameters and 
reduces the need for pharmacological treatment in 
patients with myasthenia gravis. When combined with 
standard immunosuppressive therapy, surgery gives 
more benefits as compared with steroids alone. 
Importantly it also decreases the requirement for 
steroids or immune suppressants, hence their side 
effects.12 In our study, we observed that patients in 
thymectomy group were improved clinically, 
pharmacological remission with minimal manifestation 
(MM3). Patients in non-thymectomy group had 
frequent exacerbations than thymectomy 
group.Regardless of MG condition, all patient should 
undergo thymectomy (with or without thymoma). 
Thymectomy is indicated in myasthenia gravis to 
improve clinical outcomes and reduce the need for 
immunosuppressive drugs in patients with myasthenia 
gravis.13 According to another trial, 26.0% patients 
were in complete stable remission, 35.6% patients 
were without symptoms on reduced medications, and 
17.8% patients had clinical improvement even further 
dose reduction. Overall, 79.4% of patients benefited 
with surgery, 8.2% had unchanged clinical status in 
disease, and 12.3% showed worsening clinically.14 
However, the complete stable remission rate (26.0%) 
was less as compared to other reported series 
(14%-47%).15-17 In another trial, 113 consecutive 
thymectomies were done in patients with MG, 
complications rate was 14%. Complete stable 
remission was noticed in 21% of patients, and 
significant improvement of MG in 54%, so total 
beneficial rate was 75% and 14% had unchanged 
status, and 11% (10 of 92) were worsened clinically.18 
In another trial, 42 patients with myasthenia gravis 
having thymoma were compared with 42 MG patients 
without thymoma using a modified Osserman 
classification. The mean Osserman grades at time of 
diagnosis, 6 months, 5 and 10 years post-thymectomy 
did not differ among groups. Results indicate that 
thymoma should not be considered as major poor 
prognostic factor for the long-term outcome of MG.19 
Thymectomy exhibits satisfactory long-term clinical 
benefits in patients with myasthenia gravis without 
thymic abnormalities. Although presence of anti-MuSK 
antibodies correlates with poor response to operation.20 
Thymectomy improved clinical status over a 3-year 
period in patients with myasthenia gravis without 
thymic abnormalities.
 
CONCLUSION
After thymectomy there is substantial dose reduction in 
anti myasthenic treatment with minimum or no 
exacerbation as compared to non-thymectomy 
patients. There are significant better results with 
thymectomy. So all patients of myasthenia gravis 
should be offered thymectomy as a part of treatment.
Fig 1: criteria for assessment of Myasthenia Gravis 
patients after thymectomy (MGFA-PIS)
Complete remission: pt. no S/S of MG for one year 
and no medication 
Remission CSR: no clinical weakness on examination 
Pharmacological remission: same as CSR, taking 
medicine but no on cholinesterase inhibitors 
MM: No symptoms but weakness on clinical 
examination 
MM0: pt. did not receive MG treatment for one year  
MM1: pt. is taking immunosuppression but no 
cholinesterase inhibitors
MM2: pt. is taking cholinesterase inhibitors <120mg 
pyridostigmine for a year
MM3: pt. is receiving both immunosuppressant and 
cholinesterase inhibitor
CHANGE IN STATUS
IMPROVED: a decrease in clinical manifestations or 
dose reduction in previous treatment Unchanged: no 
change in clinical manifestations or dose reduction in 
previous treatment 
WORSE: increase in pre-treatment clinical 
manifestations or dose
EXACERBATION: pt who is fulfilling criteria of CSR or 
PR but showing clinical worsening 
DIED: death of MG pt. either on treatment or after 
thymectomy
Fig 2: Comparison of outcome in both groups (p>0.05)
Fig 2: Comparison of long term outcome in both 
groups
Fig 3: Comparison of long-term outcome in 
both groups
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INTRODUCTION
Myasthenia gravis (MG) is a chronic acquired 
autoimmune disease of neuromuscular junction 
leading to muscular weakness. There are large number 
of molecules, including ion channels and various 
proteins, present at the neuromuscular junction, which 
can be targeted by autoantibodies resulting in blockage 
of neuromuscular transmission.1
Population-based studies of the epidemiology of 
myasthenia gravis have been conducted for over 50 
years. A clear increasing trend has been reported. 
Recently, estimated prevalence is about 20 per 
100,000 in United States.2 Patients with myasthenia 
gravis have fluctuating fatigability in voluntary muscles 
of body predominantly ocular, oropharyngeal, facial, 
respiratory and limbs muscles.3 The role of thymus 
gland in pathogenesis of myasthenia gravis is 
incompletely understood, but consider as major driving 
factor for the production of acetylcholine receptor 
autoantibodies. Mostly patients with myasthenia gravis 
have thymic abnormalities, i.e >50% is thymic 
hyperplasia, and 10–15% is a thymic neoplasm.4 
Treatment is with pharmacological measures with or 
without thymic surgery. Medication consists mainly of 
acetylcholinesterase inhibitors (such as neostigmine, 
pyridostigmine) which reduce the breakdown of 
acetylcholine at the neuromuscular junction and hence 
increase the amount of acetyl choline available to act 
on the remaining post synaptic receptors. Alongside 
with this symptomatic therapy, immunomodulators are 
used to dumpen the autoimmune response.5 
Thymectomy is one of the treatment modality  to treat 
MG.6 The removal of thymus gland with surgery has 
been an alternative  treatment modality  for myasthenia 
gravis since Blalock had performed a successful 
thymectomy in young female with MG and thymus 
cysts.7  We aimed to conduct this study to find the 
beneficial role of thymectomy for myasthenia Gravis 
patients in recovery from myasthenia.
We aimed to conduct this study to understand the 
potential benefits of thymectomy in our myasthenia 
gravis patients. We hypothesized that patients treated 
with thymectomy will have better clinical outcome, 
compared to the patients managed purely with 
pharmacological means.
OBJECTIVE
To compare the clinical outcome of Myasthenia Gravis 
patients treated with or without thymectomy.
MATERIAL AND METHODS
Study design: Retrospective, observational 
comparative study.
Setting: Department of Neurology, Mayo hospital, 
Lahore.
Duration: Patients with MG treated from 2014 to 
2017.
Sampling technique: Non-probability, consecutive 
sampling.
Selection criteria:
Inclusion criteria: all patients with myasthenia gravis, 
Osserman stage from 1 to 4 treated from 2014 to 
2017, irrespective of age and gender.
Exclusion criteria: Patients with recurrent myasthenia 
Gravis, ocular myasthenia with normal thymus having 
disease less than one year, HIV patients.
Data collection: After taking approval from ethical 
committee, medical record of 40 patients was 
obtained. Diagnosis of myasthenia gravis was based on 
positive EMG/RNS study, acetylcholine receptor 
antibodies and Pyridostigmine test (as Edrophonium 
was not available). Record of 20 patients that 
underwent thymectomy and 20 patients that did not 
get thymectomy was obtained. Then patients were 
called for follow-up in OPD and clinical assessment was 
be done for myasthenia Gravis. Outcome in patients 
having Thymectomy assessed on the basis of MGFA 
Post intervention. Complete remission of disease was 
defined as patients with normal muscle strength, 
without medications for myasthenia gravis for at least 
1years (fig 1). Data was entered and analysed by SPSS 
21. Both groups were compared for complete 
remission by using chi-square test and p-value≤0.05 
was considered as statistically significant
RESULTS
Study sample (total 40 patients) includes 15 males 
and 25 females. The mean age was 33 years (range 14 
to 63, SD 11.2). Table 1 In thymectomy group, 7 males 
and 13 females (age range 16 to 53 years, Mean age 
was 32, SD 10) that underwent thymectomy. With 
thymectomy, 14 patients improved, 6 remained 
unchanged while no patients showed worsened or 
exacerbated symptoms. There were 8 males and 12 
females of age 14 to 63 years that did not undergo 
thymectomy. Without thymectomy, 2 patients 
improved, 6 remained unchanged. The difference was 
significant (p<0.05). Fig 2 In both groups, complete 
stable remission was absent in all patients, 
pharmacologic remission was also nil while minimal 
manifestation status 3 was observed in all patients in 
both group (100%). Fig 3
DISCUSSION
Thymic abnormalities like Thymomas are present in 
10% of patients with myasthenia gravis, and 
thymectomy is mandatory.8 Mostly published literature 
on thymectomy has consisted of either non-randomized 
observational trials or case-control studies, mainly 
relying on remission rates.9 10 The potential benefits of 
thymectomy in improving clinical outcomes in 
myasthenia gravis (MG)  patients without thymic 
abnormalities  is still under study, despite the fact that 
it is used in clinical practice for more than  60 years.11 
thymectomy improves various clinical parameters and 
reduces the need for pharmacological treatment in 
patients with myasthenia gravis. When combined with 
standard immunosuppressive therapy, surgery gives 
more benefits as compared with steroids alone. 
Importantly it also decreases the requirement for 
steroids or immune suppressants, hence their side 
effects.12 In our study, we observed that patients in 
thymectomy group were improved clinically, 
pharmacological remission with minimal manifestation 
(MM3). Patients in non-thymectomy group had 
frequent exacerbations than thymectomy 
group.Regardless of MG condition, all patient should 
undergo thymectomy (with or without thymoma). 
Thymectomy is indicated in myasthenia gravis to 
improve clinical outcomes and reduce the need for 
immunosuppressive drugs in patients with myasthenia 
gravis.13 According to another trial, 26.0% patients 
were in complete stable remission, 35.6% patients 
were without symptoms on reduced medications, and 
17.8% patients had clinical improvement even further 
dose reduction. Overall, 79.4% of patients benefited 
with surgery, 8.2% had unchanged clinical status in 
disease, and 12.3% showed worsening clinically.14 
However, the complete stable remission rate (26.0%) 
was less as compared to other reported series 
(14%-47%).15-17 In another trial, 113 consecutive 
thymectomies were done in patients with MG, 
complications rate was 14%. Complete stable 
remission was noticed in 21% of patients, and 
significant improvement of MG in 54%, so total 
beneficial rate was 75% and 14% had unchanged 
status, and 11% (10 of 92) were worsened clinically.18 
In another trial, 42 patients with myasthenia gravis 
having thymoma were compared with 42 MG patients 
without thymoma using a modified Osserman 
classification. The mean Osserman grades at time of 
diagnosis, 6 months, 5 and 10 years post-thymectomy 
did not differ among groups. Results indicate that 
thymoma should not be considered as major poor 
prognostic factor for the long-term outcome of MG.19 
Thymectomy exhibits satisfactory long-term clinical 
benefits in patients with myasthenia gravis without 
thymic abnormalities. Although presence of anti-MuSK 
antibodies correlates with poor response to operation.20 
Thymectomy improved clinical status over a 3-year 
period in patients with myasthenia gravis without 
thymic abnormalities.
 
CONCLUSION
After thymectomy there is substantial dose reduction in 
anti myasthenic treatment with minimum or no 
exacerbation as compared to non-thymectomy 
patients. There are significant better results with 
thymectomy. So all patients of myasthenia gravis 
should be offered thymectomy as a part of treatment.
Fig 1: criteria for assessment of Myasthenia Gravis 
patients after thymectomy (MGFA-PIS)
Complete remission: pt. no S/S of MG for one year 
and no medication 
Remission CSR: no clinical weakness on examination 
Pharmacological remission: same as CSR, taking 
medicine but no on cholinesterase inhibitors 
MM: No symptoms but weakness on clinical 
examination 
MM0: pt. did not receive MG treatment for one year  
MM1: pt. is taking immunosuppression but no 
cholinesterase inhibitors
MM2: pt. is taking cholinesterase inhibitors <120mg 
pyridostigmine for a year
MM3: pt. is receiving both immunosuppressant and 
cholinesterase inhibitor
CHANGE IN STATUS
IMPROVED: a decrease in clinical manifestations or 
dose reduction in previous treatment Unchanged: no 
change in clinical manifestations or dose reduction in 
previous treatment 
WORSE: increase in pre-treatment clinical 
manifestations or dose
EXACERBATION: pt who is fulfilling criteria of CSR or 
PR but showing clinical worsening 
DIED: death of MG pt. either on treatment or after 
thymectomy
Fig 2: Comparison of outcome in both groups (p>0.05)
Fig 2: Comparison of long term outcome in both 
groups
Fig 3: Comparison of long-term outcome in 
both groups
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